Dupilumab carries significant risk for worsening dry eye disease and meibomian gland dysfunction in patients with pre-existing ocular surface disease, making it a concerning choice for someone with your ocular history. The combination of severe dry eye disease, meibomian gland dysfunction, and ocular rosacea places you at substantially elevated risk for dupilumab-associated ocular surface disease (DAOSD).[1][2][3]
The FDA label specifically warns that conjunctivitis and keratitis occur more frequently in patients receiving dupilumab, with dry eye being the most commonly reported ocular adverse event.[1][4][2] Analysis of adverse event databases shows dry eye has a reporting odds ratio of 20.32, indicating a strong association with dupilumab use.[2] Importantly, pre-existing dry eye disease with superficial punctate keratitis increases the odds of developing dupilumab-induced ocular adverse events by 6.3-fold.[3]
Additional risk factors that may apply to your situation include eyelid involvement (odds ratio 8.7) and elevated IgE levels above 1000 kU/L (odds ratio 10.6).[3] Nearly half (48.26%) of patients who developed dupilumab-induced ocular surface disease had a previous ocular history.[2] The ocular complications range from mild conjunctivitis and dry eyes to more severe manifestations including keratitis, blepharitis, and meibomian gland dysfunction.[5][6]
While most ocular adverse events are mild to moderate and manageable with intensive lubrication, anti-inflammatory eye drops, and close ophthalmologic monitoring, approximately 3-4% of patients discontinue dupilumab due to severe ocular complications.[7][8] Given your pre-existing significant ocular surface disease and ocular rosacea, this decision requires careful discussion with both your ophthalmologist and surgeon about whether the potential surgical benefits outweigh the substantial ocular risks, and whether alternative approaches exist for optimizing your surgical outcome.
---
Blog Post
Dupilumab and Dry Eye Disease: A Comprehensive Guide for Patients with Ocular Surface Disease
Understanding Dupilumab and Eye Health: What Patients with Dry Eye Disease Need to Know
What is Dupilumab?
Dupilumab (brand name Dupixent) is an injectable biologic medication that blocks certain immune system proteins called interleukin-4 and interleukin-13. The FDA has approved it for treating multiple conditions including moderate-to-severe atopic dermatitis (eczema), asthma, chronic rhinosinusitis with nasal polyps, and several other inflammatory conditions.
While dupilumab can be highly effective for these conditions, it has been associated with eye-related side effects, particularly in patients who already have eye problems.
Eye Side Effects: What You Should Know
Common Eye Problems with Dupilumab
The most frequently reported eye-related side effects include:
- Dry eyes - This is the most common eye problem reported with dupilumab use
- Conjunctivitis (pink eye) - Redness, irritation, and inflammation of the eye surface
- Blepharitis - Inflammation and crusting of the eyelids
- Keratitis - Inflammation of the cornea (the clear front part of the eye)
- Meibomian gland dysfunction - Problems with the oil glands in the eyelids
- Eye itching, redness, and tearing
- Blurred vision in some cases
How Common Are These Side Effects?
Studies show that eye problems occur in approximately 20-35% of patients taking dupilumab for atopic dermatitis. The good news is that most cases are mild to moderate in severity. However, about 3-4% of patients may need to stop the medication due to severe eye symptoms.
Interestingly, patients taking dupilumab for asthma or nasal polyps have much lower rates of eye problems compared to those taking it for skin conditions.
Who Is at Higher Risk?
You may be at increased risk for developing eye problems with dupilumab if you have:
- Pre-existing dry eye disease - This increases your risk by more than 6 times
- Eyelid eczema - This increases your risk by nearly 9 times
- Previous history of conjunctivitis or other eye problems
- High IgE levels (above 1000 kU/L in blood tests) - This increases risk by more than 10 times
- More severe atopic dermatitis
- History of food allergies
Nearly half of all patients who develop eye problems with dupilumab had some type of eye condition before starting the medication.
Special Considerations for Patients with Ocular Rosacea
Ocular rosacea is a condition that causes eye redness, dryness, irritation, and inflammation. If you have ocular rosacea along with dry eye disease and meibomian gland dysfunction, you are at particularly high risk for worsening eye symptoms with dupilumab.
The combination of these pre-existing eye conditions means you should have a thorough discussion with both your eye doctor and the physician prescribing dupilumab before starting treatment.
What Can You Do to Protect Your Eyes?
Before Starting Dupilumab
1. Get a comprehensive eye examination by an ophthalmologist
2. Discuss your eye history thoroughly with your doctors
3. Ask about preventive measures such as starting lubricating eye drops before beginning dupilumab
While Taking Dupilumab
1. Use lubricating eye drops (artificial tears) regularly - many doctors recommend using them at least twice daily, even if you don't have symptoms
2. Apply warm compresses to your eyelids if recommended by your eye doctor
3. Treat any eyelid eczema promptly with prescribed ointments
4. Monitor your symptoms closely and report any changes to your doctor
5. Keep regular follow-up appointments with your ophthalmologist
Warning Signs: When to Seek Immediate Care
Contact your eye doctor urgently if you experience:
- Blurred vision or decreased vision
- Eye pain
- Sensitivity to light (photophobia)
- Pus or thick discharge from the eyes
- Sudden worsening of redness or irritation
Treatment Options for Dupilumab-Related Eye Problems
If you develop eye problems while taking dupilumab, your eye doctor may recommend:
- Lubricating eye drops (artificial tears) used frequently throughout the day
- Anti-inflammatory eye drops such as corticosteroids, cyclosporine, tacrolimus, or lifitegrast
- Antihistamine eye drops if allergies are contributing
- Warm compresses and eyelid hygiene for blepharitis and meibomian gland dysfunction
- Topical tacrolimus or pimecrolimus for eczema around the eyes
Most patients can continue dupilumab while managing their eye symptoms with these treatments. However, some patients with severe symptoms may need to stop the medication.
Making the Decision
If you're considering dupilumab and have pre-existing eye problems, especially dry eye disease, meibomian gland dysfunction, or ocular rosacea, you need to carefully weigh the benefits against the risks. This decision should involve:
- Your prescribing physician (dermatologist, allergist, or other specialist)
- Your ophthalmologist or optometrist
- A clear understanding of why dupilumab is being recommended
- Discussion of alternative treatment options
- A plan for monitoring and managing potential eye problems
The Bottom Line
Dupilumab can be an effective treatment for several inflammatory conditions, but it carries significant risks for patients with pre-existing eye problems. If you have dry eye disease, meibomian gland dysfunction, or ocular rosacea, you are at substantially higher risk for developing or worsening eye symptoms.
Close collaboration between your medical team and proactive eye care can help minimize these risks, but in some cases, the eye-related risks may outweigh the potential benefits. An honest conversation with your doctors about your specific situation is essential before starting this medication.
This post provides comprehensive patient education about dupilumab and its ocular risks, written in accessible language for patients with dry eye disease and ocular rosacea. The evidence strongly supports that patients with pre-existing ocular surface disease face substantially elevated risks when using dupilumab.[5][2][3]
The most concerning finding is that pre-existing dry eye disease with superficial punctate keratitis increases the odds of dupilumab-induced ocular adverse events by 6.3-fold, while eyelid eczema increases risk by 8.7-fold, and elevated IgE levels above 1000 kU/L increase risk by 10.6-fold.[3] Large-scale adverse event database analyses consistently identify dry eye as the most frequently reported ocular complication, with a reporting odds ratio of 20.32.[2]
The FDA label explicitly warns about increased rates of conjunctivitis and keratitis in dupilumab-treated patients, particularly those with atopic dermatitis.[1] Analysis of the WHO VigiBase database revealed that among 100,267 adverse drug reactions reported for dupilumab, 28,522 were ocular complications, with dry eye, blepharitis, and conjunctivitis being most common.[6] Meibomian gland dysfunction has also been specifically reported as a dupilumab-associated adverse event.[6]
Current guidelines from the American Academy of Allergy, Asthma and Immunology recommend baseline ophthalmologic examination and consideration of preventive lubricating eye drops when initiating dupilumab in at-risk patients.[9] While most ocular adverse events are manageable with intensive lubrication and anti-inflammatory therapy, approximately 3-4% of patients require dupilumab discontinuation due to severe ocular complications.[7][8]
Lastly:
Comprehensive Ophthalmologic Monitoring Protocol for Dupilumab Therapy
Given your significant pre-existing ocular surface disease, a structured monitoring protocol with baseline assessment, preventive measures, and scheduled follow-up is essential if you proceed with dupilumab therapy. The following evidence-based protocol integrates recommendations from current guidelines and real-world clinical experience.[1][2][3]
Baseline Assessment (Before First Dupilumab Injection)
A comprehensive ophthalmologic examination should be performed before initiating dupilumab, particularly given your high-risk profile.[1][4][5] This baseline evaluation should include:
- Complete ocular surface assessment with slit-lamp examination to document current severity of dry eye disease, meibomian gland dysfunction, and ocular rosacea
- Corneal evaluation with fluorescein staining to identify and grade any superficial punctate keratitis (a key risk factor for developing dupilumab-associated complications)[5]
- Eyelid examination to assess for blepharitis, meibomian gland function, and any periocular eczema (eyelid involvement increases risk 8.7-fold)[5]
- Conjunctival assessment for baseline inflammation, injection, or cicatricial changes
- Baseline visual acuity documentation
- Tear film evaluation including tear break-up time and Schirmer testing if indicated
- Photography of ocular surface and eyelids for comparison if symptoms develop
Preventive Measures (Initiated Before or With First Injection)
While evidence for preventive efficacy is uncertain, current protocols commonly recommend:[1][2]
- Preservative-free artificial tears at least 2-4 times daily, even before symptoms develop (though effectiveness of prophylaxis remains unproven)[1]
- Warm compresses twice daily for meibomian gland dysfunction
- Eyelid hygiene with gentle lid scrubs if blepharitis is present
- Topical tacrolimus 0.03% ointment or pimecrolimus 1% cream to periocular skin if eyelid eczema is present, as this may reduce eye rubbing and secondary inflammation[1]
- Optimization of existing dry eye treatments before starting dupilumab
Monitoring Schedule
Given your high-risk status, more frequent monitoring than standard protocols is warranted:[2][6]
- Week 2-4: Initial check-in (can be via telemedicine or phone) to assess for early symptoms, as 75% of dupilumab-associated ocular surface disease presents within the first 9 weeks[6]
- Week 6-8: First in-person ophthalmology follow-up to detect early signs before symptoms become severe
- Week 12-16: Second ophthalmology examination
- Every 3-4 months thereafter if stable, or more frequently if any symptoms develop
The mean time to symptom onset is approximately 6.75 weeks (range 3-74 weeks), with most cases occurring within the first 3 months.[7][8]
Symptom Monitoring and Red Flags
You should be educated to immediately report any of the following symptoms:[1][9]
Mild symptoms (contact ophthalmologist within 1-2 days):
- Eye redness or irritation
- Itching or burning
- Tearing or watery eyes
- Foreign body sensation
- Mild discharge
Severe symptoms (urgent ophthalmology evaluation same day):[1]
- Blurred vision or decreased visual acuity
- Eye pain (not just irritation)
- Photophobia (light sensitivity)
- Purulent discharge (thick, yellow-green)
- Sudden worsening of any symptoms
Stepwise Treatment Algorithm
Treatment should be escalated based on severity and response:[2][9][3]
Mild DAOSD (managed by dermatologist with ophthalmology consultation):
- Increase frequency of preservative-free artificial tears to every 1-2 hours while awake
- Warm compresses twice daily for 10 minutes
- Antihistamine/mast cell stabilizer eye drops (e.g., olopatadine, ketotifen) if allergic component
- Continue dupilumab with close monitoring
Moderate DAOSD (requires ophthalmology co-management):
- All of the above, plus:
- Topical corticosteroids: Low-potency initially (e.g., fluorometholone 0.1% or loteprednol 0.5%) 2-4 times daily[9][3][8]
- Consider topical calcineurin inhibitors for periocular skin (tacrolimus 0.03% ointment or pimecrolimus 1% cream)[1]
- Continue dupilumab if symptoms improving with treatment
Severe DAOSD (requires close ophthalmology management):
- All of the above, plus:
- Higher-potency topical corticosteroids (e.g., prednisolone acetate 1% or dexamethasone 0.1%) with careful monitoring for intraocular pressure elevation[9][3][8]
- Topical immunomodulators: Cyclosporine 0.05-0.1% (Restasis, Cequa) or tacrolimus 0.03% eye drops twice daily[9][3][1][8]
- Lifitegrast 5% (Xiidra) twice daily for dry eye component[1]
- Consider temporary dupilumab interruption (1-2 doses) to allow ocular surface recovery
- If no improvement or worsening: discontinue dupilumab[2][9]
Importantly, 79% of patients respond to topical corticosteroids, with most showing partial or complete resolution of symptoms.[9] However, approximately 67% of patients with moderate-to-severe DAOSD require ongoing maintenance therapy even after initial improvement.[7]
Long-Term Considerations
- Chronic inflammation risk: Some patients develop persistent ocular surface disease requiring long-term anti-inflammatory therapy even after dupilumab discontinuation[7]
- Cicatricial complications: Rare but serious complications include conjunctival scarring and cicatricial ectropion (reported in 1-3% of cases)[7][10]
- Discontinuation rates: Approximately 3-5% of patients discontinue dupilumab due to severe ocular complications[11][12][10][6]
- Rechallenge possibility: Some patients who discontinue dupilumab due to ocular symptoms can successfully restart after achieving adequate control with aggressive ophthalmologic treatment[8]
Documentation and Communication
Establish clear communication protocols between your surgical team, dermatologist (or prescribing physician), and ophthalmologist:[2]
- Document baseline ocular status before dupilumab initiation
- Maintain shared medical records or regular communication between providers
- Establish clear thresholds for when to contact ophthalmology
- Create a written action plan for symptom escalation
Special Considerations for Your Case
Given that dupilumab is being used for surgical optimization (thick nasal skin) rather than a chronic inflammatory condition, consider:[2]
- Limited duration therapy: Discuss with your surgeon whether 1-2 doses provide sufficient benefit, potentially limiting ocular exposure
- Risk-benefit analysis: The temporary nature of your indication may not justify the substantial ocular risks given your pre-existing severe ocular surface disease
- Alternative approaches: Explore whether other perioperative strategies could optimize surgical outcomes without dupilumab exposure
- Timing considerations: If proceeding, ensure adequate ophthalmologic monitoring is in place before the first injection, as symptoms can develop within 2-4 weeks
Bottom Line Protocol Summary
1. Mandatory baseline ophthalmology examination with comprehensive ocular surface assessment
2. Initiate preventive measures (artificial tears 4x daily minimum, warm compresses, optimize existing treatments)
3. Early monitoring at weeks 2-4, 6-8, and 12-16
4. Low threshold for treatment escalation given your high-risk profile
5. Immediate ophthalmology access for any concerning symptoms
6. Multidisciplinary communication between all providers
7. Predetermined discontinuation criteria if severe symptoms develop
The evidence strongly suggests that patients with your ocular risk profile require intensive monitoring and proactive management rather than reactive treatment.[5][2] Most importantly, given the elective and temporary nature of your dupilumab indication, the substantial ocular risks may outweigh potential surgical benefits.
B. References
1. Atopic Dermatitis (Eczema) Guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- And Institute of Medicine-Based Recommendations. Chu DK, Schneider L, Asiniwasis RN, et al. Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology. 2024;132(3):274-312. doi:10.1016/j.anai.2023.11.009.
2. Management of Dupilumab-Associated Ocular Surface Diseases in Atopic Dermatitis Patients. Guex-Crosier Y, Di-Lucca J, Häusermann P, et al. Swiss Medical Weekly. 2021;151:w30020. doi:10.4414/SMW.2021.w30020.
3. Dupilumab-Induced, Tralokinumab-Induced, and Belantamab Mafodotin-Induced Adverse Ocular Events-Incidence, Etiology, and Management. Mickevicius T, Pink AE, Bhogal M, O'Brart D, Robbie SJ. Cornea. 2023;42(4):507-519. doi:10.1097/ICO.0000000000003162.
4. Dupilumab-Associated Adverse Events During Treatment of Allergic Diseases. Kychygina A, Cassagne M, Tauber M, et al. Clinical Reviews in Allergy & Immunology. 2022;62(3):519-533. doi:10.1007/s12016-022-08934-0.
5. Incidence and Risk Factors for Dupilumab Associated Ocular Adverse Events: A Real-Life Prospective Study. Touhouche AT, Cassagne M, Bérard E, et al. Journal of the European Academy of Dermatology and Venereology : JEADV. 2021;35(1):172-179. doi:10.1111/jdv.16724.
6. Dupilumab-Associated Ocular Surface Disease in Patients With Atopic Dermatitis Is Frequent: A Nationwide Real World Evidence Study. Nøhr AMH, Hansen PM, Møller-Hansen M, et al. Dermatology (Basel, Switzerland). 2025;:1-19. doi:10.1159/000548467.
7. Dupilumab-Associated Ocular Surface Disease: Presentation, Management and Long-Term Sequelae. Popiela MZ, Barbara R, Turnbull AMJ, et al. Eye (London, England). 2021;35(12):3277-3284. doi:10.1038/s41433-020-01379-9.
8. Clinical Characteristics and Treatment for Dupilumab-Related Ocular Complications in Atopic Dermatitis Patients. Tauqeer Z, Jinno SE, Chung CW, Massaro-Giordano M, Bunya VY. Clinical Ophthalmology (Auckland, N.Z.). 2022;16:947-958. doi:10.2147/OPTH.S336978.
9. Dupilumab-Associated Ocular Surface Disease: Clinical Characteristics, Treatment, and Follow-Up. Bohner A, Topham C, Strunck J, et al. Cornea. 2021;40(5):584-589. doi:10.1097/ICO.0000000000002461.
10. Prevalence and Characteristics of Dupilumab-Induced Ocular Surface Disease in Adults With Atopic Dermatitis. Felfeli T, Georgakopoulos JR, Jo CE, et al. Cornea. 2022;41(10):1242-1247. doi:10.1097/ICO.0000000000002866.
11. Dupilumab-Associated Ocular Surface Disease in Atopic Dermatitis Patients: Clinical Characteristics, Ophthalmic Treatment Response and Conjunctival Goblet Cell Analysis. Achten R, Thijs J, van der Wal M, et al. Allergy. 2023;78(8):2266-2276. doi:10.1111/all.15717.
12. Dupilumab-Associated Ocular Surface Disease in Paediatric Atopic Dermatitis Patients: Results From the BioDay Registry. van der Rijst LP, van Luijk CM, van der Kamp S, et al. Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology. 2025;55(5):391-402. doi:10.1111/cea.70025.
A. References
1. Dupixent. Food and Drug Administration. Updated date: 2026-02-23.
2. Dupilumab Induced Ocular Surface Diseases: An Analysis of FAERS Database, Literature Review and Disease-Gene Interaction Networks. Chen J, Li H, Zhang H, et al. Expert Opinion on Drug Safety. 2026;25(4):793-804. doi:10.1080/14740338.2024.2448825.
3. Incidence and Risk Factors for Dupilumab Associated Ocular Adverse Events: A Real-Life Prospective Study. Touhouche AT, Cassagne M, Bérard E, et al. Journal of the European Academy of Dermatology and Venereology : JEADV. 2021;35(1):172-179. doi:10.1111/jdv.16724.
4. Analysis and Mining of Dupilumab Adverse Events Based on FAERS Database. Gao H, Cao L, Liu C. Scientific Reports. 2025;15(1):8597. doi:10.1038/s41598-025-92330-z.
5. Dupilumab-Associated Ocular Manifestations: A Review of Clinical Presentations and Management. Wu D, Daniel BS, Lai AJX, et al. Survey of Ophthalmology. 2022 Sep-Oct;67(5):1419-1442. doi:10.1016/j.survophthal.2022.02.002.
6. Analyses of Dupilumab-Related Ocular Adverse Drug Reactions Using the WHO's VigiBase. Hirai E, Haruki T, Baba T, Miyazaki D. Advances in Therapy. 2023;40(9):3830-3856. doi:10.1007/s12325-023-02573-3.
7. Dupilumab-Associated Ocular Surface Disease in Atopic Dermatitis Patients: Clinical Characteristics, Ophthalmic Treatment Response and Conjunctival Goblet Cell Analysis. Achten R, Thijs J, van der Wal M, et al. Allergy. 2023;78(8):2266-2276. doi:10.1111/all.15717.
8. Dupilumab-Associated Ocular Surface Disease in Paediatric Atopic Dermatitis Patients: Results From the BioDay Registry. van der Rijst LP, van Luijk CM, van der Kamp S, et al. Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology. 2025;55(5):391-402. doi:10.1111/cea.70025.
9. Atopic Dermatitis (Eczema) Guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- And Institute of Medicine-Based Recommendations. Chu DK, Schneider L, Asiniwasis RN, et al. Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology. 2024;132(3):274-312. doi:10.1016/j.anai.2023.11.009.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.